{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:39Z","timestamp":1787010219711,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Adrenal suppression (AS) is an iatrogenic, life-threatening condition that can occur after glucocorticoid exposure. Despite recognition that AS occurs after induction phase treatment in children with acute lymphoblastic leukemia (ALL), the risk of AS in phases beyond induction is unknown. We conducted a pilot study in pediatric patients with ALL to ascertain whether the risk of AS persists in post-induction phases of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedure:<\/jats:title>\n                    <jats:p>Patients diagnosed between 12 months to younger than 18 years with B or T-ALL and starting any new phase of treatment were eligible for the study. Relapsed or infant ALL were excluded. Low dose ACTH stimulation testing (LDST), measurement of albumin and cortisol binding globulin were performed in all patients. Screening for symptoms of AS was done.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-four patients enrolled in the study. One was diagnosed with clear AS. Five others had a borderline cortisol peak, representing possible mild AS. Symptoms were nonspecific and did not help distinguish patients with normal LDST from those with borderline or abnormal results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients on treatment for ALL continue to be at risk of AS beyond induction treatment. Although this risk appears small, physicians must be vigilant as patients may be asymptomatic but could develop adrenal crisis during treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000002784","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T10:03:00Z","timestamp":1699437780000},"page":"46-50","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Adrenal Suppression in Children During the Treatment for Acute Lymphoblastic Leukemia Beyond Induction"],"prefix":"10.1097","volume":"46","author":[{"given":"Ren\u00e9e-Pier","family":"Fortin-Boudreault","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology-Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ahmet","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics, Children\u2019s Hospital of Eastern Ontario, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics, Children\u2019s Hospital of Eastern Ontario, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Pat","family":"Schlosser","sequence":"additional","affiliation":[{"name":"Division of Pediatric Immunology\/Allergy, Hematology\/Oncology, Palliative Care and Environmental Health, Stollery Children\u2019s Hospital, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myl\u00e8ne","family":"Bassal","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"e000569","DOI":"10.1136\/bmjpo-2019-000569","article-title":"Adrenal suppression from glucocorticoids: preventing an iatrogenic cause of morbidity and mortality in children","volume":"3","author":"Ahmet","year":"2019","journal-title":"BMJ Paediatr Open"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00431-020-03624-5","article-title":"Adrenal function after induction therapy for acute lymphoblastic leukemia in children short: adrenal function in ALL","volume":"179","author":"Loimijoki","year":"2020","journal-title":"Eur J Pediatr"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1179\/1607845414Y.0000000208","article-title":"A prospective study of the hypothalamic-pituitary-adrenal axis in children with acute lymphoblastic leukemia receiving chemotherapy","volume":"20","author":"Salem","year":"2015","journal-title":"Hematology"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MPH.0b013e3182260cbe","article-title":"Duration of adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia","volume":"33","author":"Vestergaard","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/08880018.2018.1539148","article-title":"Prolonged adrenal insufficiency after high-dose glucocorticoid in infants with leukemia","volume":"35","author":"Moritani","year":"2018","journal-title":"Pediatr Hematol Oncol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/pbc.21339","article-title":"Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia","volume":"50","author":"Einaudi","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdw557","article-title":"Infection-related complications during treatment for childhood acute lymphoblastic leukemia","volume":"28","author":"Inaba","year":"2017","journal-title":"Ann Oncol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000262532","article-title":"Pitfalls in the diagnosis of central adrenal insufficiency in children","volume":"17","author":"Kazlauskaite","year":"2010","journal-title":"Endocr Dev"},{"key":"R11-20250804","first-page":"CD008727","article-title":"Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia","volume":"11","author":"Rensen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jpeds.2005.06.006","article-title":"Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test","volume":"147","author":"Rix","year":"2005","journal-title":"J Pediatr"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1515\/jpem-2017-0270","article-title":"The role of corticosteroid-binding globulin in the evaluation of adrenal insufficiency","volume":"31","author":"Verbeeten","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/acr.23123","article-title":"Frequency and duration of adrenal suppression following glucocorticoid therapy in children with rheumatic diseases","volume":"69","author":"Ahmet","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S2213-2600(18)30058-4","article-title":"Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study","volume":"6","author":"Hawcutt","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/pch\/pxab015","article-title":"Adrenal suppression from exogenous glucocorticoids: Recognizing risk factors and preventing morbidity","volume":"26","author":"Ahmet","year":"2021","journal-title":"Paediatr Child Health"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1210\/jc.2008-0710","article-title":"Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis","volume":"93","author":"Kazlauskaite","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00134-009-1480-x","article-title":"Serum free cortisol index, free cortisol, and total cortisol in critically ill children","volume":"35","author":"Poomthavorn","year":"2009","journal-title":"Intensive Care Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:03:34Z","timestamp":1754337814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002784","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"2023-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}